

## Special Issue

# Advances in Human Monkeypox Vaccines Effectiveness, Safety and Hesitancy

### Message from the Guest Editor

The human monkeypox (HMPX) outbreak of 2022 did not only cause several thousands of cases in non-endemic countries but also triggered multi-faceted debates about epidemic preparedness, discontinuation of smallpox vaccination, effectiveness and safety of the repurposed smallpox vaccines and drugs, and public interest in (acceptance of) immunization against orthopoxviruses. I am pleased to invite you to participate in this Special Issue which aims to delve into three main thematic areas. Firstly, the effectiveness of the repurposed smallpox vaccines that are used as pre- or post-exposure prophylaxis needs to be evaluated within the context of the ongoing outbreak, especially among high-risk groups and healthcare settings. Secondly, pre- and post-authorization safety of HMPX vaccines and antivirals should be actively monitored in order to update the current immunization guidelines in light of the best available evidence. Thirdly, vaccination acceptance and misconceptions among healthcare professionals, students, and high-risk groups are of utmost importance amid this outbreak because they may either accelerate or unnecessarily delay the task of epidemic control.

### Guest Editor

Dr. Abanoub Riad

1. Department of Public Health, Faculty of Medicine, Masaryk University, 625 00 Brno, Czech Republic
2. Institute of Health Information and Statistics of the Czech Republic (IHIS-CR), 128 01 Prague, Czech Republic
3. Czech National Center of Evidence-based Healthcare and Knowledge Translation (Cochrane Czech Republic, Czech EBHC: JBI Centre of Excellence, Masaryk University GRADE Centre), Faculty of Medicine, Masaryk University, 625 00 Brno, Czech Republic

### Deadline for manuscript submissions

closed (20 October 2024)



## Vaccines

an Open Access Journal  
by MDPI

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/si/146082](https://mdpi.com/si/146082)

*Vaccines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)

[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)





# Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)



## About the Journal

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

---

### Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,  
University of Georgia, Athens, GA 30602-7387, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /  
CiteScore - Q1 (Pharmacology (medical))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).